Acasti Pharma Inc. (ACST)
NASDAQ: ACST · Real-Time Price · USD
3.020
-0.090 (-2.89%)
At close: Oct 8, 2024, 4:00 PM
3.205
+0.185 (6.14%)
After-hours: Oct 8, 2024, 4:04 PM EDT
Acasti Pharma Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Revenue | - | - | - | - | 0.2 | - | |
Cost of Revenue | - | - | - | - | 0.08 | - | |
Gross Profit | - | - | - | - | 0.12 | - | |
Selling, General & Admin | 7.07 | 6.68 | 8.28 | 6.58 | 6.66 | 8.46 | |
Research & Development | 6.21 | 4.59 | 9.93 | 5.56 | 4.17 | 15.97 | |
Operating Expenses | 13.27 | 11.28 | 18.21 | 12.14 | 10.84 | 24.44 | |
Operating Income | -13.27 | -11.28 | -18.21 | -12.14 | -10.72 | -24.44 | |
Interest Expense | - | - | - | - | -0.26 | -0.25 | |
Interest & Investment Income | 1.01 | 0.91 | 0.25 | 0.08 | 0.11 | 0.34 | |
Currency Exchange Gain (Loss) | -0.03 | -0.02 | -0.07 | -0.3 | -0.68 | -0 | |
Other Non Operating Income (Expenses) | -1.33 | -2.73 | 0.01 | 5.34 | -2.43 | -1.16 | |
EBT Excluding Unusual Items | -13.62 | -13.11 | -18.02 | -7.02 | -13.98 | -25.51 | |
Merger & Restructuring Charges | - | -1.49 | -33.51 | -3.2 | - | - | |
Asset Writedown | -0.09 | -0.09 | -0.44 | -0.25 | -5.7 | - | |
Pretax Income | -13.71 | -14.69 | -51.97 | -10.47 | -19.68 | -25.51 | |
Income Tax Expense | -2.27 | -1.83 | -9.54 | -0.65 | - | - | |
Net Income | -11.45 | -12.85 | -42.43 | -9.82 | -19.68 | -25.51 | |
Net Income to Common | -11.45 | -12.85 | -42.43 | -9.82 | -19.68 | -25.51 | |
Shares Outstanding (Basic) | 10 | 10 | 7 | 6 | 2 | 2 | |
Shares Outstanding (Diluted) | 10 | 10 | 7 | 6 | 2 | 2 | |
Shares Change (YoY) | 39.68% | 28.16% | 21.09% | 148.46% | 40.25% | 55.80% | |
EPS (Basic) | -1.10 | -1.35 | -5.71 | -1.60 | -7.96 | -14.48 | |
EPS (Diluted) | -1.10 | -1.35 | -5.71 | -1.60 | -7.96 | -14.48 | |
Free Cash Flow | -9.71 | -12.36 | -15.93 | -17.23 | -14.39 | -23.27 | |
Free Cash Flow Per Share | -0.93 | -1.30 | -2.14 | -2.81 | -5.82 | -13.21 | |
Gross Margin | - | - | - | - | 61.22% | - | |
Operating Margin | - | - | - | - | -5467.35% | - | |
Profit Margin | - | - | - | - | -10039.80% | - | |
Free Cash Flow Margin | - | - | - | - | -7340.82% | - | |
EBITDA | -13.27 | -11.27 | -18.08 | -11.22 | -9.79 | -22.12 | |
D&A For EBITDA | 0.01 | 0.01 | 0.12 | 0.92 | 0.92 | 2.32 | |
EBIT | -13.27 | -11.28 | -18.21 | -12.14 | -10.72 | -24.44 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.